Related Experiment Videos
Long-term experience of self-injection therapy with prostaglandin E1 for erectile dysfunction
L Lundberg1, J O Olsson, B Kihl
1Section of Urology, Department of Surgery, Central Hospital, Karlstad, Sweden.
Scandinavian Journal of Urology and Nephrology
|October 1, 1996
Summary
Intracavernous injection of prostaglandin E1 is a long-term treatment option for erectile dysfunction. Over half of patients continued using this method for nearly four years, with no major complications reported.
Area of Science:
- Urology
- Andrology
- Sexual Medicine
Background:
- Erectile dysfunction (ED) affects a significant number of men.
- Intracavernous injections are a treatment modality for ED.
- Long-term outcomes of prostaglandin E1 injections for ED require further investigation.
Purpose of the Study:
- To evaluate the long-term efficacy and patient experience with intracavernous prostaglandin E1 for erectile dysfunction.
- To determine the continuation rates and reasons for discontinuation of this treatment.
Main Methods:
- Retrospective study involving 42 male patients aged 36-80 years with ED.
- Treatment administered via intracavernous injection of prostaglandin E1.
- Long-term patient experience assessed via questionnaire.
Main Results:
- 57% of patients (24/42) continued using prostaglandin E1 injections after an average of 46.9 months.
- 43% of patients (18/42) discontinued the treatment after an average of 21.4 months.
- No major complications were reported during the study period.
Conclusions:
- Intracavernous prostaglandin E1 demonstrates sustained usability for a majority of patients with erectile dysfunction over the long term.
- The treatment is associated with a low rate of major complications.
- Further research could explore factors influencing long-term adherence and discontinuation.